Galoczova, Michaela
Nenutil, Rudolf
Pokorna, Zuzana
Vojtesek, Borivoj
Coates, Philip J. http://orcid.org/0000-0003-1518-6306
Funding for this research was provided by:
Grantová Agentura České Republiky (19-06530S)
European Regional Development Fund (CZ.02.1.01/0.0/0.0/16_019/0000868)
Ministry of Health (MMCI 00209805)
Ministerstvo Školství, Mládeže a Tělovýchovy (LM2018125)
EU Horizon 2020 (676550)
Article History
Received: 21 April 2020
Revised: 25 September 2020
Accepted: 1 October 2020
First Online: 10 October 2020
Compliance with ethical standards
:
: BV is a consultant for and RN is a co-owner of Moravian Biotechnology, who originally produced the p63 monoclonal antibodies used in this study. The company did not provide financial support or have any influence over the design, execution, or interpretation of the data. MG, ZP, and PJC declare that they have no competing interests.
: The study was performed retrospectively on redundant excess tissues. All patient data were anonymized. In accordance with the Declaration of Helsinki and the regulations of the European Union, the use of excess and redundant tissues was approved following local ethical committee review by the Biobanking and Biomolecular resources Research Infrastructure (BBMRI) at the Masaryk Memorial Cancer Institute, Brno. Patient consent is not required for the retrospective use of anonymized, redundant excess tissues.
: Not applicable.
: Not applicable.